Myelofibrosis is associated with severe, frequent symptom burden1
Progressive, relentless symptoms impair QoL and increase disability2-4
- MF-related symptoms compromise social functioning, physical activity, independence, and QoL1,5
- Constitutional MF symptoms negatively impact QoL and are associated with poor prognosis for survival4,6
- Fatigue is extremely common and is similar to or worse than that suffered by patients undergoing chemotherapy for haematologic malignancies7
High incidence and wide variety of symptoms of MF1

Adapted from: Scherber R et al. Blood. 2011;118:401-408.1
QoL scores for MF patients were worse than those for all cancer patients combined8
Mean baseline EORTC QLQ-C30 HRQoL scores for patients with MF (COMFORT-II) compared with scores for all cancer patients by age group8

Adapted from: Kiladjian J et al. Poster presented at ASCO Annual Meeting, 2012.8
Learn more about QoL improvement with JAKAVI
MF-related symptoms are progressive and may worsen even with conventional therapies9,10
Symptom scores worsened with placebo9

Adapted from: Verstovsek S et al. N Engl J Med. 2012;366:799-807.9
Symptoms measured with the use of a modified Myelofibrosis Symptom Assessment Form (MFSAF), version 2.0.
Symptoms scores worsened from baseline with conventional therapies throughout 48-week study period10

Adapted from: Harrison C et al. N Engl J Med. 2012;366:787-798.10
Symptoms measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core model.
Learn more about significant symptom improvement with JAKAVI